Hoechst GmbH, a prominent player in the pharmaceutical and biotechnology sectors, is headquartered in Germany (DE). Founded in the late 19th century, the company has evolved significantly, becoming a key subsidiary of Sanofi, a global healthcare leader. Hoechst operates primarily in Europe, with a strong presence in various international markets. Specialising in innovative medicines and healthcare solutions, Hoechst GmbH is renowned for its commitment to research and development, particularly in areas such as oncology, cardiovascular health, and vaccines. The company’s unique approach to drug formulation and delivery sets it apart in a competitive landscape. With a rich history of milestones, Hoechst has established itself as a trusted name in the industry, consistently achieving notable advancements in patient care and therapeutic efficacy. Its dedication to quality and innovation solidifies its market position as a leader in the pharmaceutical field.
How does Hoechst GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hoechst GmbH's score of 100 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hoechst GmbH, headquartered in Germany (DE), currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Sanofi, from which it inherits climate commitments and initiatives. Sanofi has established significant climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are cascaded to Hoechst GmbH, aligning with industry standards and best practices. The initiatives include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on sourcing 100% renewable electricity. While Hoechst GmbH does not have its own specific reduction targets or achievements reported, it benefits from the overarching climate strategies implemented by Sanofi, which aim to enhance sustainability and reduce carbon footprints across its subsidiaries. The commitment to climate action reflects a broader industry trend towards transparency and accountability in emissions management.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hoechst GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.